We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · October 07, 2021

Patritumab Deruxtecan (HER3-DXd) in EGFR TKI–Resistant, EGFR-Mutated NSCLC

Cancer Discovery


Additional Info

Cancer Discovery
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
Cancer Discov 2021 Sep 21;[EPub Ahead of Print], PA Janne, C Baik, WC Su, ML Johnson, H Hayashi, M Nishio, DW Kim, M Koczywas, KA Gold, CE Steuer, H Murakami, JC Yang, SW Kim, M Vigliotti, R Shi, Z Qi, Y Qiu, L Zhao, D Sternberg, C Yu, HA Yu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading